This calculator is provided for informational and educational purposes only. It is not intended to replace professional medical advice, diagnosis, or treatment. Always consult with a qualified healthcare professional before making any medical decisions. The results from this calculator should be used as a reference guide only and not as the sole basis for clinical decisions.
PAGE-B Score Calculator
Estimate 5-year hepatocellular carcinoma (HCC) risk in treated chronic hepatitis B using the validated PAGE-B scoring system – enter platelet count, patient age, and sex to receive an instant HCC risk category, reference range display, and clinical surveillance guidance based on Papatheodoridis et al. 2016.
PAGE-B risk classification based on Papatheodoridis et al. Gastroenterology 2016. Current patient score highlighted in the table.
| PAGE-B Score | Risk Category | 5-Year HCC Risk | Surveillance Recommendation | Your Score |
|---|---|---|---|---|
| 0 to 9 | Low Risk | ~1% | Standard 6-monthly ultrasound | |
| 10 to 17 | Intermediate Risk | ~3 to 5% | 6-monthly ultrasound, consider AFP and LSM | |
| 18 to 24 | High Risk | ~10%+ | Intensive surveillance, specialist referral |
Detailed scoring criteria for each PAGE-B component. Current patient values highlighted. Maximum total score is 24 points.
| Component | Criterion | Points | Clinical Basis | Current Patient |
|---|---|---|---|---|
| Age | 16 to 29 years | 0 | Lowest cumulative HBV exposure | |
| Age | 30 to 39 years | 2 | Early accumulation of viral injury | |
| Age | 40 to 49 years | 4 | Moderate fibrosis accumulation | |
| Age | 50 to 59 years | 6 | Advanced fibrosis risk period | |
| Age | 60 to 69 years | 8 | High cumulative injury burden | |
| Age | 70 years or older | 10 | Highest age-related HCC risk | |
| Sex | Female | 0 | Hormonal protection, lower androgen effect | |
| Sex | Male | 6 | 2-4x higher HCC incidence than female | |
| Platelet Count | 200 x10^9/L or above | 0 | Normal – preserved liver architecture | |
| Platelet Count | 100 to 199 x10^9/L | 4 | Mild portal hypertension, moderate fibrosis | |
| Platelet Count | Below 100 x10^9/L | 8 | Severe portal hypertension, cirrhosis likely |
How different patient profiles score on the PAGE-B scale. Your current score is shown for comparison.
| Patient Profile | PAGE-B Score | Score Bar | Risk Category |
|---|---|---|---|
| Female, age 25, platelets 250 | 0 | Low | |
| Male, age 35, platelets 220 | 8 | Low | |
| Male, age 45, platelets 160 | 14 | Intermediate | |
| Your patient (score 16) | 16 | Intermediate | |
| Male, age 55, platelets 150 | 16 | Intermediate | |
| Male, age 65, platelets 90 | 22 | High | |
| Male, age 70+, platelets below 100 | 24 | High |
This calculator is provided for informational and educational purposes only. It is not intended to replace professional medical advice, diagnosis, or treatment. Always consult with a qualified healthcare professional before making any medical decisions. The results from this calculator should be used as a reference guide only and not as the sole basis for clinical decisions.
About This PAGE-B Score Calculator
This PAGE-B score calculator is designed for hepatologists, gastroenterologists, specialist nurses, and primary care clinicians managing adults with chronic hepatitis B on antiviral therapy. It calculates the validated PAGE-B score – a three-variable clinical tool that estimates the 5-year risk of hepatocellular carcinoma (HCC) in patients receiving nucleos(t)ide analogue treatment. By entering the patient’s age, biological sex, and most recent platelet count, clinicians receive an instant total score from 0 to 24, a visual zone bar showing where the score falls on the low, intermediate, or high HCC risk scale, and a per-component reference range panel displaying the individual contribution of each variable.
The calculator applies the scoring algorithm derived by Papatheodoridis and colleagues (Gastroenterology, 2016): age contributes 0 to 10 points in 2-point increments per decade from age 30, male sex contributes 6 points reflecting the 2 to 4 times higher HCC incidence in men, and platelet count contributes 0, 4, or 8 points based on thresholds of 200, 100 to 199, or below 100 x10^9/L – each threshold representing increasing degrees of portal hypertension and liver fibrosis. The three tabs below the calculator provide a PAGE-B severity reference table, a detailed scoring criteria breakdown, and a score comparison table showing how the current patient’s result compares against representative clinical profiles.
The PAGE-B score fills a practical clinical need: once antiviral therapy normalises viral load and ALT levels, viral parameters lose discriminative power and simpler models based on routinely available data become more reliable for ongoing HCC risk stratification. This tool enables clinicians to calculate and document the PAGE-B score at each clinic visit, identify patients in the high-risk category (score 18 to 24) who may benefit from enhanced surveillance or specialist review, and communicate risk clearly to patients as part of shared decision-making. Annual recalculation is recommended for all patients on long-term antiviral therapy. Clinical judgement must always complement the score.
PAGE-B Score Calculator – Complete Guide to Predicting HCC Risk in Chronic Hepatitis B
The PAGE-B score is a validated, non-invasive clinical scoring tool designed to estimate the 5-year risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB) who are receiving antiviral therapy. Unlike older models that required liver biopsy or complex imaging, PAGE-B uses three readily available parameters – age, sex, and platelet count – making it practical for use in both specialist clinics and resource-limited settings worldwide.
HCC remains one of the most common and lethal cancers globally, with chronic hepatitis B infection accounting for the majority of cases. Early identification of high-risk patients allows clinicians to intensify surveillance, optimise treatment strategies, and potentially intervene before malignant transformation occurs. The PAGE-B score fills a critical gap by providing reliable risk stratification during antiviral treatment, when other markers such as viral load and ALT levels may normalise and no longer distinguish patients by cancer risk.
Sex: Male = 6 pts | Female = 0 pts
Platelet count (x10^9/L): 200 or above = 0 pts | 100 to 199 = 4 pts | Below 100 = 8 pts
Total Score Range: 0 to 24 points
Development and Validation of the PAGE-B Score
The PAGE-B score was developed by Papatheodoridis and colleagues, published in a landmark study in the journal Gastroenterology (2016). The derivation cohort included European patients with chronic hepatitis B on nucleos(t)ide analogue (NA) therapy, predominantly entecavir or tenofovir. The score achieved high discriminative accuracy in the development cohort and was subsequently validated in independent European and Asian populations.
The name PAGE-B is an acronym derived from its three input variables: Platelets, Age, Gender, and the disease context (Hepatitis B). The simplicity of the model was intentional – the investigators sought a tool that could be applied without additional blood tests, imaging, or biopsy, using only parameters routinely collected at clinic visits.
The original validation showed a c-statistic (AUROC) of approximately 0.82 in European cohorts, indicating good discriminative ability. Subsequent validation in Asian cohorts has yielded comparable or slightly variable performance, with most studies confirming its utility across diverse populations. Some studies in East Asian cohorts have suggested modest recalibration may improve accuracy, but the unadjusted score remains widely used clinically.
Understanding the Three Components
The three variables in the PAGE-B score were selected through multivariable regression analysis, each reflecting a distinct biological mechanism underlying HCC risk.
Age is the strongest predictor of HCC in chronic hepatitis B, independent of treatment status. Older patients have accumulated greater cumulative viral replication, longer duration of hepatic inflammation and fibrosis, and greater cellular replicative senescence. Age-related immune dysfunction may also impair viral suppression at the cellular level. In the PAGE-B model, each decade of age above 30 adds 2 points to the score, reflecting a consistent and near-linear increase in cancer risk with advancing age.
Sex contributes 6 points for male patients, reflecting the well-established male predominance in HCC development. Men with chronic hepatitis B carry approximately 2 to 4 times the HCC risk of women at equivalent levels of fibrosis and viral activity. This difference is attributable to higher androgen receptor expression in hepatocytes, sex differences in immune responses to HBV, lower rates of viral clearance in men, and differences in comorbid alcohol use and metabolic risk factors.
Platelet count serves as a validated surrogate marker for portal hypertension and advanced liver fibrosis. As fibrosis progresses to cirrhosis, portal hypertension leads to splenomegaly and platelet sequestration, while reduced thrombopoietin production by the failing liver further suppresses platelet production. A platelet count below 100 x10^9/L is a reliable indicator of clinically significant portal hypertension, and patients at this level carry substantially elevated HCC risk.
The PAGE-B score was specifically developed for patients already receiving antiviral therapy (nucleos(t)ide analogues). It should not be applied to untreated patients, where different risk models – such as the CU-HCC score or REACH-B score – are more appropriate. In treated patients, viral suppression normalises many biochemical markers, making simple algorithms based on age, sex, and platelets more robust than complex models incorporating viral parameters.
Risk Stratification Categories and Clinical Implications
The PAGE-B score divides patients into three risk categories based on their 5-year probability of developing HCC:
Intermediate Risk (10 to 17 points): 5-year HCC risk approximately 3 to 5% – regular 6-monthly surveillance mandatory
High Risk (18 to 24 points): 5-year HCC risk approximately 10% or above – intensive surveillance, specialist review
For low-risk patients (score 0 to 9), some guidelines have explored whether surveillance intervals could be extended or simplified. However, the majority of major society guidelines – including the European Association for the Study of the Liver (EASL), the American Association for the Study of Liver Diseases (AASLD), and the Asian Pacific Association for the Study of the Liver (APASL) – continue to recommend 6-monthly ultrasound surveillance for all patients with chronic hepatitis B regardless of risk category.
Intermediate-risk patients (score 10 to 17) represent the majority of those in clinical practice and require consistent adherence to standard surveillance protocols. Clinicians may consider additional investigations such as AFP-L3, des-gamma-carboxyprothrombin (DCP/PIVKA-II), or liver stiffness measurement (LSM) via transient elastography to further refine individual risk.
High-risk patients (score 18 or above) warrant the most intensive clinical attention. This includes consideration of enhanced surveillance protocols, earlier discussion of treatment response adequacy, referral to specialist hepatology or liver oncology teams, and assessment for concurrent risk factors such as cirrhosis, diabetes, metabolic syndrome, and alcohol use.
Comparison with Other HCC Risk Scores in Treated Chronic Hepatitis B
Several validated scoring systems exist for predicting HCC risk in chronic hepatitis B. The mPAGE-B score (modified PAGE-B) adds serum albumin to the three original PAGE-B variables and demonstrated superior discrimination in validation studies, particularly in Asian populations. The CAMD score uses cirrhosis status, age, male sex, and diabetes – incorporating a clinical diagnosis of cirrhosis rather than a surrogate marker like platelet count. More complex models such as the REAL-B and HCC-RESCUE scores incorporate liver stiffness or additional biochemical parameters but are less practical for routine use.
In head-to-head comparative studies, PAGE-B and mPAGE-B consistently outperform REACH-B when applied to NA-treated populations, confirming the importance of using treatment-specific risk models.
Performance of PAGE-B Across Different Ethnic Populations
The PAGE-B score has been validated in diverse geographic and ethnic populations. In European populations (the derivation context), PAGE-B achieves AUROC values of 0.80 to 0.84 with well-calibrated risk estimates. In East Asian populations (predominantly Korean, Chinese, and Taiwanese cohorts), PAGE-B demonstrates AUROC values of 0.73 to 0.80. Some studies suggest modest underestimation of HCC risk in Asian patients, potentially because HCC can arise at earlier fibrosis stages due to perinatal infection acquisition and longer disease duration.
In South Asian and sub-Saharan African populations, limited validation data exist. Given the high burden of HBV-related HCC in these regions, further prospective validation is warranted. Across all populations studied, the direction of risk associations (higher age, male sex, and lower platelets increasing HCC risk) is consistent, suggesting the biological relationships are universal even if the precise numerical accuracy varies.
PAGE-B and Liver Fibrosis Assessment
Although the PAGE-B score does not directly incorporate liver fibrosis stage, its platelet component functions as a surrogate for advanced fibrosis and cirrhosis. Liver stiffness measurement (LSM) by transient elastography (FibroScan) is now widely available and provides a continuous fibrosis estimate. Several studies have examined whether combining LSM with PAGE-B improves risk prediction. PAGE-B retains its practical advantage in settings where elastography is unavailable or unreliable (e.g., in patients with high BMI, ascites, or significant hepatic inflammation).
The EASL guidelines acknowledge that in patients with compensated advanced chronic liver disease (cACLD, defined as LSM 10 to 15 kPa), additional risk stratification using scores like PAGE-B can guide surveillance intensity. In patients with definite cirrhosis (LSM above 15 kPa), HCC surveillance is recommended regardless of PAGE-B category.
Surveillance Protocols and When to Apply PAGE-B
HCC surveillance in chronic hepatitis B is recommended by all major hepatology guidelines. The standard protocol is abdominal ultrasound every 6 months, with or without serum alpha-fetoprotein (AFP). The PAGE-B score adds value in patients without confirmed cirrhosis, where the decision to initiate or intensify surveillance may otherwise be uncertain. In non-cirrhotic patients on antiviral therapy, a high PAGE-B score justifies maintaining strict 6-monthly surveillance despite the absence of cirrhosis.
The score is most appropriately applied at baseline when antiviral therapy is initiated, and can be recalculated at subsequent visits. Since platelet count may change with treatment response or disease progression, serial calculation captures dynamic changes in risk over time. Some experts recommend annual recalculation in all patients on long-term NA therapy.
The PAGE-B score provides population-level risk estimates based on three variables. Individual patients may carry HCC risk factors not captured by the score, including coexisting NAFLD, significant alcohol use, family history of HCC, diabetes, and coinfection with HCV or HDV. Clinical assessment must integrate PAGE-B results with a comprehensive review of these additional factors.
Limitations of the PAGE-B Score
Despite its widespread clinical application, the PAGE-B score has important limitations. The score was derived in European patients receiving specific antiviral agents; its applicability to patients with suboptimal viral suppression is less well established. PAGE-B assigns binary weight to sex, not accounting for post-menopausal women who lose hormonal protection. The platelet thresholds create artificial categories from a continuous variable, and laboratory variation may affect classification near threshold values. The 5-year risk estimates are population averages, not precise individual predictions. The score also does not incorporate treatment response data or emerging biomarkers such as HBsAg quantification and HBcrAg levels.
HCC and Chronic Hepatitis B – Global Disease Burden
Hepatocellular carcinoma is the sixth most common cancer and the third leading cause of cancer-related mortality worldwide, with over 900,000 new cases diagnosed annually. Approximately 50 to 60% of HCC cases globally are attributable to chronic hepatitis B virus infection, with the highest burden concentrated in sub-Saharan Africa and East Asia.
Despite effective antiviral therapies that achieve viral suppression in more than 95% of treated patients, antiviral therapy does not eliminate HCC risk. Long-term studies of patients on entecavir and tenofovir confirm that while NA therapy substantially reduces HCC incidence, patients with advanced fibrosis or cirrhosis at treatment initiation remain at significantly elevated risk for decades after achieving undetectable HBV DNA.
Nucleos(t)ide Analogues and Their Impact on PAGE-B Score Components
Long-term antiviral therapy affects two of the three PAGE-B components. Age increases monotonically with treatment duration. Platelet count, however, may change during treatment. In patients with advanced fibrosis or compensated cirrhosis, effective viral suppression can lead to fibrosis regression and clinically meaningful increases in platelet count as portal hypertension ameliorates. A patient who was high-risk at treatment initiation due to low platelets may, after several years of therapy-induced fibrosis regression, experience platelet recovery that lowers their PAGE-B category. This dynamic reflects genuine risk reduction.
Integration with Clinical Decision-Making and Multidisciplinary Care
In practice, the PAGE-B score is most useful as part of a structured hepatitis B clinic review. At the time of antiviral therapy initiation, the score provides an immediate risk category that can guide the initial surveillance approach and inform patient counselling. Within multidisciplinary teams, PAGE-B offers a standardised, reproducible metric for risk communication between hepatologists, specialist nurses, gastroenterologists, and primary care physicians.
Frequently Asked Questions
Conclusion
The PAGE-B score represents a clinically practical, validated, and widely applicable tool for HCC risk stratification in adults with chronic hepatitis B receiving antiviral therapy. Its three-variable structure – age, sex, and platelet count – enables rapid calculation at every clinic visit using routinely available data, without the need for additional blood tests, imaging, or liver biopsy.
The score’s risk categories (low: 0 to 9, intermediate: 10 to 17, high: 18 to 24) provide clinically meaningful guidance for surveillance intensity, patient counselling, and resource allocation. While it does not replace comprehensive clinical evaluation, PAGE-B has established itself as an essential component of the hepatitis B specialist’s toolkit. All patients with chronic hepatitis B on antiviral therapy should have their PAGE-B score calculated, documented, and reviewed annually as part of routine clinical care.